巴洛伐坦治疗孤独症成人社交沟通困难:3期随机安慰剂对照试验
V1aduct是一项3期随机双盲安慰剂对照试验,在北美和欧洲46个中心纳入322名18岁以上中重度孤独症谱系障碍成人,评估巴洛伐坦10mg每日一次共24周对Vineland-II两域复合评分的影响。结果显示巴洛伐坦组与安慰剂组在第24周评分变化上无显著差异,试验因无效提前终止,巴洛伐坦未改善社交沟通,耐受性良好。
要点
- 巴洛伐坦10mg每日一次治疗24周未改善孤独症成人Vineland-II两域复合评分。
- 第24周最终分析中巴洛伐坦组评分变化4.56 vs 安慰剂组6.83,方向不利于巴洛伐坦。
- 巴洛伐坦耐受性良好,两组不良事件比例相似,无治疗相关死亡。
核心结论
- 巴洛伐坦未改善孤独症成人的社交沟通能力。
- 该研究提示孤独症谱系障碍试验面临挑战,包括相当大的安慰剂反应和合适结局指标的选择。
研究设计与样本
- V1aduct为3期随机、安慰剂对照、双盲试验,在6个国家(美国、英国、法国、意大利、西班牙、加拿大)的46个中心开展。
- 纳入标准为年龄18岁及以上、智商70及以上、符合DSM-5和孤独症诊断观察量表的中重度孤独症谱系障碍标准。
- 参与者按1:1随机分配接受巴洛伐坦10mg或安慰剂每日一次共24周,随机化按基线Vineland-II两域复合评分(<60或≥60)、性别、地区(北美或世界其他地区)和年龄(<25岁或≥25岁)分层。
- 主要终点为第24周Vineland-II两域复合评分(社交化和沟通域的平均复合评分)较基线的变化,主要分析采用ANCOVA在意向治疗人群中进行。
- 试验在约50%参与者完成第24周访视后因无效而终止。
主要发现
- 2018年8月8日至2020年7月1日期间筛查540人,322人被分配接受巴洛伐坦(164例[51%])或安慰剂(158例[49%])。
- 巴洛伐坦组1例在试验终止前未接受治疗并被排除分析;巴洛伐坦组60例和安慰剂组55例在第24周前终止治疗。
- 样本包括64例(20%)女性和257例(80%)男性,260例(81%)来自北美,61例(19%)来自欧洲;基线平均年龄27.6岁(SD 9.7),平均智商104.8(18.1)。
- interim无效分析显示第24周Vineland-II两域复合评分较基线变化的最小二乘均值:巴洛伐坦组2.91(SE 1.52,n=79)vs 安慰剂组4.75(SE 1.60,n=71),估计治疗差异-1.84(95%CI -5.15至1.48)。
- 最终分析中第24周Vineland-II两域复合评分较基线平均变化:巴洛伐坦组4.56(SD 10.85,n=111)vs 安慰剂组6.83(SD 12.18,n=99)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 试验因无效提前终止,约50%参与者完成第24周访视。
- 原文指出孤独症谱系障碍试验面临挑战,包括相当大的安慰剂反应和合适结局指标的选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are no approved pharmacological therapies to support treatment of the core communication and socialisation difficulties associated with autism spectrum disorder in adults. We aimed to assess the efficacy, safety, and pharmacokinetics of balovaptan, a vasopressin 1a receptor antagonist, versus placebo in autistic adults. METHODS: V1aduct was a phase 3, randomised, placebo-controlled, double-blind trial, conducted at 46 sites across six countries (the USA, the UK, France, Italy, Spain, and Canada). Eligible participants were aged 18 years or older with an intelligence quotient (IQ) of 70 or higher, and met the criteria for moderate-to-severe autism spectrum disorder (DSM-5 and Autism Diagnostic Observation Schedule). Participants were randomly allocated (1:1), with an independent interactive voice or web-based response system, to receive balovaptan (10 mg) or placebo daily for 24 weeks. Randomisation was stratified by an individual's baseline Vineland-II two-domain composite (2DC) score (<60 or ≥60), sex, region (North America or rest of world), and age (<25 years or ≥25 years). Participants, study site personnel, and the sponsor were masked to treatment assignment. The primary endpoint was change from baseline in Vineland-II 2DC score (the mean composite score across the Vineland-II socialisation and communication domains) at week 24. The primary analysis was done with ANCOVA in the intention-to-treat population. The V1aduct study was terminated for futility after around 50% of participants completed the week 24 visit. This trial is registered with ClinicalTrials.gov (NCT03504917). FINDINGS: Between Aug 8, 2018, and July 1, 2020, 540 people were screened for eligibility, of whom 322 were allocated to receive balovaptan (164 [51%]) or placebo (158 [49%]). One participant from the balovaptan group was not treated before trial termination and was excluded from the analysis. 60 participants in the balovaptan group and 55 in the placebo group discontinued treatment before week 24. The sample consisted of 64 (20%) women and 257 (80%) men, with 260 (81%) participants from North America and 61 (19%) from Europe. At baseline, mean age was 27·6 years (SD 9·7) and mean IQ score was 104·8 (18·1). Two (1%) participants were American Indian or Alaska Native, eight (2%) were Asian, 15 (5%) were Black or African American, 283 (88%) were White, four (1%) were of multiple races, and nine (3%) were of unknown race. Mean baseline Vineland-II 2DC scores were 67·2 (SD 15·3) in the balovaptan group and 66·2 (17·7) in the placebo group. The interim futility analysis showed no improvement for balovaptan versus placebo in terms of Vineland-II 2DC score at week 24 compared with baseline, with a least-squares mean change of 2·91 (SE 1·52) in the balovaptan group (n=79) and 4·75 (1·60) in the placebo group (n=71; estimated treatment difference -1·84 [95% CI -5·15 to 1·48]). In the final analysis, mean change from baseline in Vineland-II 2DC score at week 24 was 4·56 (SD 10·85) in the balovaptan group (n=111) and 6·83 (12·18) in the placebo group (n=99). Balovaptan was well tolerated, with similar proportions of participants with at least one adverse event in the balovaptan group (98 [60%] of 163) and placebo group (104 [66%] of 158). The most common adverse events were nasopharyngitis (14 [9%] in the balovaptan group and 19 [12%] in the placebo group), diarrhoea (11 [7%] and 14 [9%]), upper respiratory tract infection (ten [6%] and nine [6%]), insomnia (five [3%] and eight [5%]), oropharyngeal pain (five [3%] and eight [5%]), and dizziness (two [1%] and ten [6%]). Serious adverse events were reported for two (1%) participants in the balovaptan group (one each of suicidal ideation and schizoaffective disorder), and five (3%) participants in the placebo group (one each of suicidal ideation, panic disorder, limb abscess, urosepsis, colitis [in the same participant with urosepsis], and death by suicide). No treatment-related deaths occurred. INTERPRETATION: Balovaptan did not improve social communication in autistic adults. This study provides insights into challenges facing autism spectrum disorder trials, including the considerable placebo response and the selection of appropriate outcome measures. FUNDING: F Hoffmann-La Roche.
引用
- Jacob S, Veenstra-VanderWeele J, Murphy D, et al. Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial. Lancet Psychiatry. 2022. PMID: 35151410. doi:10.1016/S2215-0366(21)00429-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。